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LOBELINE COMPOUNDS AS A TREATMENT 
FOR PSYCHOSTIMULANT ABUSE AND 
WITHDRAWAL, AND FOR EATING 
DISORDERS 
FIELD OF THE INVENTION 
The present invention relates to the use of lobeline and 
analogs thereof in the treatment of drugs of abuse and 
WithdraWal therefrom. The invention also relates to the 
treatment of eating disorders, such as obesity. 
BACKGROUND OF THE INVENTION 
Lobeline (ot-lobeline) is a lipophilic, non-pyridino, alka 
loidal constituent of Indian tobacco (Lobelia in?ata). As 
shoWn by the following formulas, no obvious structural 
resemblance to S(—)nicotine is apparent: 
/ N 
| | 
\ CH3 
N 
S(—) Nicotine 
4 
OH 3 5 O 
H‘, 2 1 6 H 
8 ¢ ’ ' 7 “ ~ 10 
7 If 9 
CH3 
Structure-function relationships betWeen nicotine and 
lobeline do not suggest a common pharmacophore (BarloW 
and Johnson, 1989). Nonetheless, lobeline has been reported 
to have many nicotine-like effects including tachycardia and 
hypertension (Olin et al., 1995), bradycardia and hypoten 
sion in urethane and pentobarbital anesthetiZed rats (Sloan et 
al., 1988), hyperalgesia (Hamann and Martin, 1994), mid 
olytic activity (Brioni et al., 1993), and improvement of 
learning and memory (Decker et al., 1993). Moreover, 
lobeline has been used as a substitution therapy for tobacco 
smoking cessation (Nunn-Thompson and Simon, 1989; 
Prignot, 1989; Olin et al., 1995); hoWever, its effectiveness 
is controversial as re?ected by both positive (Dorsey, 1936; 
KalyuZhnyy, 1968) and negative reports (Wright and 
Littauer, 1937; Nunn-Thompson and Simon, 1989). 
Furthermore, only short-term usage of lobeline as a smoking 
deterrent has been recommended due to its acute toxicity 
(nausea, severe heartburn and diZZiness) and the lack of 
information concerning its long-term usage (Wright and 
Littauer, 1937; Olin et al., 1995). 
In behavioral studies, nicotine has been shoWn to increase 
locomotor activity (Clarke and Kumar, 1983a, 1983b; 
Clarke, 1990; Fung and Lau, 1988), and to produce condi 
tioned place preference (Shoaib et al., 1984); Fudala et al., 
1985) in rats. HoWever, the results of the latter studies are 
controversial (Clarke and Fibiger, 1987). In contrast, 
lobeline does not increase locomotor activity (Stolerman et 
al., 1995) or produce conditioned place preference (Fudala 
and IWamoto, 1986). Although initially lobeline Was shoWn 
to generaliZe to nicotine in discrimination studies (Geller et 
al., 1971), most subsequent studies have failed to reproduce 
this original ?nding (Schechter and Rosecrans, 1972; 
Reavill et al., 1990; Romano and Goldstein, 1980). 
10 
15 
20 
25 
30 
35 
40 
45 
55 
60 
65 
2 
Nicotine has been reported to be avidly self-administered 
by rats (Corrigal et al. 1992, 1994; Donny et al., 1996); 
hoWever, the ability of lobeline to support self 
administration has not been investigated. Based on the 
differential effects of lobeline and nicotine in behavioral 
studies, it appears that these drugs may not be acting via a 
common CNS mechanism, even though lobeline is often 
considered to be a nicotinic agonist (Decker et al., 1995). 
The positive reinforcing effect of nicotine is believed to be 
due to the activation of central dopaminergic systems 
(BoWell and Balfour, 1992; Corrigal et al., 1992, 1994). 
Presynaptic nicotinic receptors have been found on dopam 
ine (DA)-containing nerve terminals (Giorguieff-Chesselet 
et al., 1979; Clarke and Pert, 1985). Nicotine binds to 
nicotinic receptors With high affinity (Kd=1—7 nM) 
(Lippiello and Fernandes, 1986; Reavill et al., 1988; Romm 
et al., 1990; Bhat et al., 1991; Loiacono et al., 1993; 
Anderson and Arneric, 1994). Also, lobeline has been 
reported to displace [3H]nicotine binding from central nico 
tinic receptors With high affinity (Ki=5—30 nM) (Yamada et 
al., 1985; Lippiello and Fernades, 1986; Banerjee and 
Abood, 1989; Broussolle et al., 1989). 
Chronic treatment With nicotine results in an increase in 
the number of nicotinic receptors in many regions of rat and 
mouse brain (Collins et al., 1990; Bhat et al., 1991, 1994; 
Marks et al., 1992; Sanderson et al., 1993). An increase in 
the number of nicotinic receptors in postmortem human 
brain tissue obtained from smokers also has been reported 
(BenWell et al., 1988). In contrast, chronic lobeline admin 
istration did not increase the number of nicotinic receptors 
in mouse brain regions in Which increases Were observed 
folloWing chronic nicotine administration (Bhat et al., 
1991). 
Nicotine evokes DA release in in vitro superfusion studies 
using striatal slices (Westfall, 1974; Giorguieff-Chesselet et 
al., 1979; Westfall et al., 1987; Harsing et al., 1992) and 
striatal synaptosomes (Chesselet, 1984; RoWell et al., 1987; 
Rapier et al., 1988, 1990; Grady et al., 1992, 1994; RoWell 
and Hillebrand, 1992, 1994; RoWell, 1995), and in in vivo 
studies using microdialysis in striatum (Imperato et al., 
1986; Damsma et al., 1989; BraZell et al., 1990; Toth et al, 
1992). Nicotine-evoked DA release is calcium-dependent, 
mecamylamine-sensitive and mediated by nicotinic recep 
tors (Giorguieff-Chesselet et al., 1979; Westfall et al, 1987; 
Rapier et al., 1988; Grady et al., 1992). Mecamylamine is a 
noncompetitive nicotinic receptor antagonist, Which more 
effectively blocks the ion channel of the receptor (Varanda 
et al., 1985; Loiacono et al., 1993; Peng et al., 1994). Similar 
to nicotine, lobeline has been reported to increase DA 
release from superfused rat and mouse striatal synaptosomes 
(Sakurai et al., 1982; Takano et al, 1983; Grady et al., 1992). 
Based on these neurochemical studies, lobeline Was sug 
gested to be an agonist at nicotinic receptors. It is difficult to 
reconcile that nicotine and lobeline similarly release DA and 
displace [3H]nicotine binding; hoWever, the observed 
upregulation of nicotinic receptors folloWing chronic nico 
tine administration is not observed folloWing chronic 
lobeline administration. 
Earlier studies of the pharmacokinetic properties of 
lobeline have centered on its proposed use in the treatment 
of nicotinism. For example, US. Pat. Nos. 5,536,503; 5,486, 
362; 5,403,595; and PCT Publication WO 92/19241 are all 
related to a drug delivery system and method for treating 
nicotine dependence. US. Pat. Nos. 5,414,005; 4,971,079; 
and 3,901,248 also discuss the use of lobeline in the conteXt 
of treating nicotine abuse and/or addiction. A scienti?c 
article has studied the actions of morphine, lobeline, and 
5,830,904 
3 
other drugs in inducing “analgesia” in rats (S. Hamann et al. 
1994). However, these Workers did not equate their ?nding 
of an “analgesic” response for lobeline to a reduction of the 
pain response in man, nor did they propose the use of 
lobeline in treating drug abuse, WithdraWal from addiction, 
and the like. 
Similarly, to the present inventors’ knowledge, the use of 
lobeline in the treatment of eating disorders has not been 
proposed. This is in spite of the Widely accepted ability of 
nicotine to suppress appetite (see, e.g., Remington’s Pharm. 
Sci, 18th ed., p.891) and the previously proposed associa 
tion of obesity With reduced bioavailability of dopamine 
(US. Pat. Nos. 5,552,429; 5,576,321; 5,272,144; and 5,468, 
755). 
SUMMARY OF THE INVENTION 
In its broadest aspect, the present invention is for a 
method of treating an individual for drug dependence, 
WithdraWal from drug dependence, or for an eating disorder. 
The method comprises administering to the individual an 
amount of a lobeline compound, i.e., lobeline, analogs, and 
derivatives thereof, including pharmaceutically acceptable 
salts. The amount of lobeline compound administered is 
effective to reduce the individual’s desire for the drug of 
abuse or for food. The lobeline compound can be adminis 
tered alone, combined With an excipient, or coadministered 
With a second drug having a similar or synergistic effect. The 
compound or composition is preferably administered 
subcutaneously, intramuscularly, intravenously, 
transdermally, orally, intranasally, or rectally. 
The utility of lobeline, analogs, and derivatives thereof, 
e.g., those that form lobeline upon metabolism by the body, 
in treating dependencies on drugs of abuse is implicated by 
the present studies. In particular, the treatment of dependen 
cies on such drugs as cocaine, amphetamines, caffeine, 
phencyclidine, opiates, barbiturates, benZodiaZepines, 
cannabinoids, hallucinogens, and alcohol is implicated. 
Also, the treatment of eating disorders, such as obesity, is 
implicated. 
In a preferred aspect of the invention, the method of 
treatment reduces an individual’s desire for the drug of 
abuse or for food by at least one day. It is also preferred that 
the treatment method further comprise administering behav 
ior modi?cation counseling to the individual. 
Although a lobeline compound of the present invention is 
contemplated primarily for use in the treatment of drug 
abuse and WithdraWal, and for eating disorders, other uses 
are also suggested by the studies discussed herein. Thus, 
cognitive disorders, brain trauma, memory loss, psychosis, 
sleep disorders, obsessive-compulsive disorders, panic 
disorders, and related conditions are considered to be sus 
ceptible to treatment With a lobeline compound of the 
present invention. 
As shoWn by the results of the studies described herein, 
and contrary to conventional belief, lobeline is found to act 
at higher concentrations primarily not as a nicotinic agonist, 
but by a different mechanism than is observed for nicotine. 
While not Wishing to be bound by any particular theory, it 
is believed that the lipophilic nature of lobeline permits it to 
diffuse passively into neurotransmitter-containing vesicles 
of cells found in the central nervous system (CNS), Where it 
is effective in inducing the release of intracellular dopamine. 
The present studies also suggest that lobeline may be 
effective in inhibiting uptake of extracellular dopamine by 
cells of the CNS, perhaps by blocking dopamine receptors 
on the cells. Either or both mechanisms can thereby Work to 
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increase the extracellular concentration of dopamine. Many 
respects in Which the actions of lobeline are similar to those 
of amphetamine have been identi?ed. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. 1(A) and 1(B) depicts the time course of nicotine 
evoked fractional release (A) and concentration-dependence 
of nicotine-evoked total [3H]over?oW (D) from rat striatal 
slices preloaded With [3H]DA (3,4-dihydroxyphenylethyl-2 
[N-3H]-amine). Nicotine Was added to the superfusion 
buffer after the second sample (as indicated by the arroW) 
and remained in the buffer until the end of the experiment. 
The data in FIG. 1A are presented as means:S.E. fractional 
release, Which represents the tritium in the sample as a 
percentage of the total tritium in the slice at the time of 
sample collection. The data in FIG. 1B are presented as 
mean:S.E. total [3H]over?oW, Which represents the area 
under the curve of the corresponding nicotine concentration 
response as a function of time. § P<0.05, different from basal 
(5—10 min), When fractional release Was collapsed across 
nicotine concentration; *P<0.05, signi?cantly different from 
0—0.01 pM and 1—100 pM; **P<0.05, different from 0—0.1 
pM and 100 pM; ***P<0.05, different from 0—10 pM; 
Duncan’s NeW Multiple Range Test. n=4—9 rats. 
FIGS. 2(A) and 2(B) depict the time course of lobeline 
evoked fractional release from rat striatal slices preloaded 
With [3H]DA. Lobeline Was added to the superfusion buffer 
after the collection of the second sample (as indicated by the 
arroW) and remained in the buffer until the end of the 
experiment. Data are presented as mean:S.E. fractional 
release, Which represents the tritium in the superfusate 
sample as a percentage of the total tritium in the slice at the 
time of sample collection. FIG. 2A illustrates the time course 
of the fractional release evoked by loW concentrations 
(0.01—3 pM) of lobeline, and FIG. 2B illustrates that evoked 
by high concentrations (3—100 pM). *P<0.05, different from 
basal out?oW; +P<0.05, different from the peak responses at 
25 min for 0.01—3 pM and 30—300 pM; § P<0.05, different 
from the peak responses of 0.01—10 pM and 100 pM; # 
P<0.05, different from the peak responses of 0.01—30 pM; 
Fisher’s LSD post hoc test. n=6 rats. 
FIG. 3 depicts the concentration-dependence of lobeline 
evoked total [3H]over?oW from rat striatal slices preloaded 
With [3H]DA. Data are presented as mean:S.E. total [3H] 
over?oW, Which represents the area under the curve of the 
corresponding lobeline concentration-response as a function 
of time. The inset illustrates the total [3H]over?oW evoked 
by the loWer concentrations (0.01—1 pM) of lobeline. Con 
trol slices Which Were superfused With buffer in the absence 
of lobeline did not evoke [3H]over?oW (i.e. fractional 
release Was not different from basal during the course of 
superfusion). * P<0.05, different from control and each of 
the other lobeline concentrations; Duncan’s NeW Multiple 
Range Test. n=6 rats. 
FIG. 4 depicts the time course of the effect of mecamy 
lamine to inhibit nicotine (10 pM)-evoked fractional release 
of [3H]DA from preloaded rat stratal slices. For clarity of 
graphical presentation, only signi?cant effects of the loWest 
and highest concentration, 0.01 and 100 pM, respectively, of 
mecamylamine are illustrated. Data are presented as 
mean:S.E. fractional release as percentage of basal out?oW. 
Experiments Were performed as described in Table 2 here 
inbeloW. The time course begins at the time of nicotine (10 
pM) addition to the superfusion buffer containing mecamy 
lamine. The control represents fractional release in the 
absence of either mecamylamine or nicotine in the super 
5,830,904 
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fusion buffer. Duncan’s NeW Multiple Range Test revealed 
a signi?cant inhibitory effect of 0.01 pM mecamylamine, 
When the data Were collapsed across time of superfusion. 
n=8 rats. 
FIG. 5 depicts the effects of nicotine (0.01—1000 pM) and 
lobeline (0.01—1000 pM) on rat striatal synaptosomal and 
synaptic vesicular [3H]DA uptake. III nicotine, synaptoso 
mal [3H]DA uptake; I nicotine, vesicular [3H]DA uptake; 0 
lobeline, synaptosomal [3H]DA uptake; . lobeline, vesicu 
lar [3H]DA uptake. Data are presented as mean:S.E. per 
centage of total [3H]DA uptake. Total [3H]DA uptake for 
synaptosomes and vesicles Was 10919.80 pmol/min/mg and 
13401717 pmol/min/mg, respectively. Non-speci?c [3H] 
DA uptake in synaptosomal and vesicular experiments Was 
2% and 20%, respectively, of total [3H]DA uptake as deter 
mined by incubation With 10 pM GBR and incubation at 0° 
C., respectively. Experiments examining the effect of nico 
tine on synaptosomal uptake included a loW concentration 
range (0.001—1 nM), hoWever, no effect Was observed and 
for clarity of graphical presentation these results are not 
illustrated. *P<0.05, different from total [3H]DA uptake; 
Dunnett’s post hoc test. n=3—6 rats. 
FIG. 6 depicts the endogenous DA and DOPAC 
(dihydroxyphenylacetic acid) content in rat striatal slices 
superfused With high concentrations (30—100 pM) of 
lobeline. Endogenous DA and DOPAC content Were deter 
mined after 60 min superfusion With various concentrations 
of lobeline. Data are presented as mean:S.E. ng/mg protein. 
*P<0.05, different from control, P<0.05, **P<0.001, differ 
ent from control; Dunnett’s post hoc test. n=8 rats. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As used herein, the term “lobeline” refers to a compound 
having the general chemical formula 2-[6-([3 
hydroxyphenethyl)-1-methyl-2-piperidyl]-acetophenone. 
The term “lobeline” as used herein refers to the above 
compound in its free form, or as a salt thereof, Which has the 
physiological activity addressed. Inasmuch as a compound 
having this formula has three chiral centers, eight optical 
isomers of the compound can exist. HoWever, particular 
optical isomer(s) are not intended herein unless speci?cally 
mentioned. 
The term “lobeline analogs” and equivalents thereof, as 
used herein, refers to chemical derivatives of lobeline, such 
as those obtained by oxidation or reduction of lobeline, 
others obtained by esteri?cation of lobeline and its redox 
derivatives, as Well as various substitutions at the N-position 
of the piperidinyl group in the lobeline molecule. 
Preferred lobeline analogs,, Which may act as prodrugs of 
lobeline itself When metaboliZed by the body, include those 
contemplated by formula (I) (Without regard to chirality): 
(I) 
Where R1 and R2 each independently represents hydrogen, 
loWer alkyl, loWer alkenyl, loWer alkylcarbonyl, 
arylcarbonyl, aralkylcarbonyl, loWer alkoxycarbonyl, loWer 
alkylaminocarbonyl, higher alkylcarbonyl, and poly 
(alkyleneoxide)carbonyl; R3 and R4 each independently 
represents hydrogen or combines With R1 and R2, 
respectively, to form a double bond; and X represents H or 
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loWer alkyl. Whenever a carbonyl-containing substituent is 
provided as R1 or R2, it is understood that the carbonyl group 
is covalently bonded to the respective O atom appearing in 
formula Thus, in the instances Where the substituent is an 
alkoxycarbonyl or alkylaminocarbonyl, a carbonate or car 
bamate linkage is present in the molecule. 
Preferred substituents for R1 and R2 include methylcar 
bonyl (acetyl), phenylcarbonyl (benZoyl), natural fatty acid 
groups, e.g., palmitoyl, oleyl, linoleyl, stearyl, and lauryl, 
and polyethyleneglycol (PEG) covalently bonded to the 
molecule via a carbonate linkage. Long chain moieties such 
as a PEG group in a lobeline prodrug enhance transdermal 
delivery of the molecule, Which may be metaboliZed to 
lobeline and derivatives thereof. 
As used herein, the terms “loWer alkyl”, “loWer alkenyl”, 
“loWer alkoxy”, and the like, refer to normal, branched and 
cyclic hydrocarbyl groups containing 1 to 6 carbon atoms. 
The term “higher alkyl” includes alkyl groups containing 7 
to about 20 carbon atoms. The term “aryl” refers to a 
hydrocarbon group containing one or more aromatic rings, 
optionally substituted With one or more heteroatoms. The 
term “aralkyl” refers to an aryl group covalently bonded to 
a loWer alkyl group. 
It is, of course, contemplated that certain lobeline analogs 
having the above formula may be converted into a different 
molecule upon metabolism by the body. For example, When 
ever an acetyl group is present at R1 and/or R2 in the 
compound, the acetyl group may be removed by metabolic 
processes, e.g., such as occur in the gastrointestinal tract or 
the liver. The choice of substituents is subject to consider 
ations of toxicity, side effects, dosage, and the like. 
Particularly preferred lobeline analogs are those in Which 
(i) both R1 and R2 are H (i.e., a lobelanidine compound), (ii) 
either R1 or R2 is H and the other combines With R3 or R4 
to form a double bond (i.e., a lobeline compound), and (iii) 
both R1 and R2 combine With either R3 or R4 to form a 
double bond (i.e., a lobelanine compound). It is also pre 
ferred that X in the above formula represents a methyl 
group. Preferably, the chirality at the 2 and 6 positions of the 
piperidyl ring of the compounds is the same as in naturally 
occurring lobeline. 
Lobeline, as Well as analogs thereof, can be administered 
in its free base form or as a soluble salt. Whenever it is 
desired to employ a salt of lobeline or analog, it is preferred 
that a soluble salt be employed. Some preferred salts include 
the hydrochloride, hydrobromide, nitrate, sulfate, tartrate, 
fumarate, citrate, maleate, ascorbate, lactate, aspartate, 
mesylate, benZene sulfonate, propionate and succinate salts. 
Also, other anionic moieties such as fatty acid salts can be 
used, e.g., palmitate salt. 
As used herein, an “effective amount”, and similar usages, 
refers to an amount of a drug effective to reduce an indi 
vidual’s desire for a drug of abuse, or for food. 
Apharmaceutical composition containing a lobeline com 
pound of the invention is also contemplated, Which may 
include a conventional additive such as a stabiliZer, buffer, 
salt, perservative, ?ller, ?avor enhancer, and the like, as 
knoWn to those skilled in the art. Representative buffers 
include phosphates, carbonates, citrates, and the like. Exem 
plary preservatives include EDTA, EGTA, BHA, BHT, and 
the like. 
A composition of the invention may be administered by 
inhalation, i.e., intranasally as an aerosol or nasal formula 
tion; topically, i.e., in the form of an ointment, cream or 
lotion; orally, i.e., in solid or liquid form (tablet, gelcap, time 
release capsule, poWder, solution, or suspension in aqueous 
or non-aqueous liquid); intravenously as an infusion or 
injection, i.e., as a solution, suspension, or emulsion in a 
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pharmaceutically acceptable carrier; transdermally, e.g., via 
a transdermal patch; rectally, as a suppository, and the like. 
Generally, it is expected that a pharmacologically effec 
tive dose of a present compound Will require its adminis 
tration in an amount less than 1><10_3 mg/kg of body Weight 
per day. The amount to be administered depends to some 
extent on the lipophilicity of the speci?c compound selected, 
since it is expected that this property of the compound Will 
cause it to partition into fatty deposits of the subject. The 
precise amount to be administered can be determined by the 
skilled practitioner in vieW of desired dosages, side effects, 
the medical history of the patient, and the like. It is antici 
pated that the compound Will be administered in an amount 
ranging from about 1><10_5 to about 1><10_3 mg/kg/day. 
The present study Was performed to determine the 
involvement of nicotinic receptors in lobeline-evoked [3H] 
over?oW from rat striatal slices preloaded With [3H]DA. The 
calcium-dependency of the effect of lobeline and the ability 
of mecamylamine to inhibit the lobeline response Were 
determined. To assess the contribution of potential effects on 
DA uptake, the effect of nicotine and lobeline to inhibit 
[3H]DA uptake into striatal synaptosomes and synaptic 
vesicle preparations Was also determined. Based on the 
present results of the in vitro superfusion studies, striatal 
dopamines (DA) and dihydroxy phenylacetic acid (DOPAC) 
content Were also determined after lobeline superfusion in 
vitro, and after lobeline administration in vivo. 
Effect of nicotine on superfused rat striatal slices preloaded 
With [3H]DA 
In a concentration-dependent manner, nicotine evoked an 
increase in the fractional release of tritium over the time 
course of the superfusion experiment (FIG. 1A). Repeated 
measures, tWo-Way AN OVA (analysis of variants) revealed 
a signi?cant main effect of nicotine concentration (F(8)429) 
=29.45, P<0.0001) and a signi?cant main effect of time 
(F(1O)429)=9.76, P<0.0001), but the concentration><time inter 
action Was not signi?cant (F(8O>42O)=1.22, P>0.05). Frac 
tional release peaked Within 10—15 min after the addition of 
nicotine to the superfusion buffer. From 10—25 min after the 
addition of nicotine, fractional release Was signi?cantly 
increased above basal out?oW, When the data Were collapsed 
across nicotine concentration. At peak fractional release, the 
highest concentration of nicotine examined increased frac 
tional release 2-fold above basal. Furthermore, When the 
data Were collapsed across nicotine concentration, fractional 
release, from 30—45 min after nicotine addition, Was not 
signi?cantly different from basal, despite the presence of 
nicotine in the superfusion buffer throughout the superfusion 
period. 
Presentation of the results as nicotine-evoked total [3H] 
over?oW accentuates the concentration-dependent nature of 
the response to nicotine (FIG. 1B). Repeated-measures, 
one-Way ANOVA revealed a signi?cant nicotine 
concentration effect (F(8>39)=25.77, P<0.0001). The loWest 
nicotine concentration Which evoked a signi?cant increase 
in [3H]over?oW Was 0.05 pM. A plateau in the 
concentration-response curve Was not apparent over the 
concentration range examined. Higher concentrations of 
nicotine Were not examined because of the extensive Work 
of Westfall and collaborators (Westfall, 1974; Westfall et al., 
1987) indicating that nicotine concentrations higher than 
100 pM act to release DA from superfused rat striatal slices 
by a mechanism Which is not calcium-dependent nor 
nicotinic-receptor mediated. 
Effect of lobeline on superfused rat striatal slices preloaded 
With [3H]DA 
Lobeline evoked a marked concentration-dependent 
increase in fractional release of tritium over the time course 
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of the superfusion experiment (FIG. 2). Repeated-measures, 
tWo-Way ANOVA revealed a signi?cant main effect of 
lobeline concentration (F7)363=1057.13, P<0.0001), a sig 
ni?cant main effect of time (F(1O>363)=132.24, P<0.0001) and 
a signi?cant concentration><time interaction (F(7O)363)= 
44.85, P<0.0001). LoW concentrations (0.01—1 pM) of 
lobeline did not signi?cantly increase fractional release 
during the entire superfusion period. Lobeline (3 pM) 
evoked a signi?cant increase in fractional release 15 and 20 
min after its addiction to the buffer. Subsequently, the 
fractional release returned toWards basal, despite the con 
tinuous presence of lobeline in the buffer. Fractional release 
evoked by high concentrations (10—100 pM) of lobeline Was 
signi?cantly increased 10 min after the addition of lobeline 
to the buffer and remained signi?cantly higher than basal 
until the end of the experiment. 
Of note is the magnitude of the response to lobeline in 
comparison to that observed after superfusion With nicotine. 
Peak fractional release after superfusion With 30 and 100 pM 
lobeline Was approximately 15% and 30%, respectively, of 
the total tritium present in the striatal slice (FIG. 2B). 
Furthermore, over the remainder of the superfusion period, 
fractional release in superfusate samples continued to be 
10—20% of the total tritium in the slice. On the other hand, 
peak fractional release induced by the highest concentration 
(100 pM) of nicotine Was only 2% of total tritium in the 
slice, and fractional release returned to basal during the 
course of the experiment (FIG. 1A). These results suggest 
the potential for depletion of DA storage pools folloWing 
superfusion With lobeline at high concentrations. 
Expression of the results as total [3H]over?oW also 
revealed a concentration-dependent effect of lobeline and a 
marked increase in [3H]over?oW evoked by high concen 
trations of lobeline (FIG. 3). Repeated-measures, one-Way 
AN OVA revealed a signi?cant lobeline concentration effect 
(F(6>35)=61.55, P< 0.0001). The loWest concentration of 
lobeline to evoke a signi?cant increase in total [3H]over?oW 
Was 1 pM. As the lobeline concentration Was increased, a 
signi?cantly greater total [3H]over?oW Was evoked. 
Furthermore, a plateau in the concentration-response curve 
Was not apparent over the concentration range examined. 
Lobeline-induced [3H]over?oW: Lack of calcium 
dependency 
Previous studies (Westfall, 1974; Westfall et al., 1987) 
reported that nicotine (<100 pM)-evoked [3H]over?oW from 
rat striatal slices preloaded With [3H]over?oW Was calcium 
dependent. In order to determine if lobeline-induced [3H] 
over?oW Was calcium-dependent, the effect of lobeline Was 
determined in a calcium-free superfusion buffer containing 
0.5 mM EGTA (ethylene glycol-bis([3-aminoethyl ether)-N, 
N,N‘,N‘-tetraacetic acid (See Table 1). TWo-Way ANOVA 
revealed a signi?cant main effect of lobeline concentration 
(Within-group factor, F(3>39)=473.08, P<0.001), hoWever, the 
main effect of inclusion of calcium in the buffer Was not 
signi?cant (betWeen-groups factor, F(1>39)=0.13, P>0.05) 
and the interaction term also Was not signi?cant (F(3)39)= 
1.64, P>0.05). Thus, the effect of lobeline on [3H]over?oW 
Was not altered folloWing removal of calcium from the 
superfusion buffer. 
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TABLE 1 
Lobeline Evokes [3H]Overflow from Rat Striatal Slices Preloaded 
with [3H]DA in a Calcium-Independent Manner" 
Lobeline 
Concentration Control Buffer Calcium-Free Buffer 
0.1 0.6 1 0.4 0 1 0 
1 2.0 1 0.6 2.9 1 0.2 
10 31.9 1 2.2 45.0 1 4.2 
100 198.0 1 20 185.0 1 12.0 
*Concentration-response of lobeline was determined using either control 
Krebs’ buffer or calcium-free buffer with the addition of 0.5 mM EGTA. Data 
are presented as mean 1 SE. total [3H]over?ow, n = 6 rats/group. 
Nicotine-evoked and lobeline-evoked [3H]over?ow: 
mecamylamine antagonism 
In a concentration-dependent manner, mecam lamine sig 
ni?cantly inhibited nicotine (10 pM)-evoked [ H]over?ow 
from rat striatal slices preloaded with [3H]DA (See Table 2). 
Repeated-measures, one-way AN OVA revealed a signi?cant 
mecamylamine concentration effect (F(5>38)=4.46, P<0.005). 
Concentrations of mecamylamine from 0.1—100 pM inhib 
ited (57%—91%) the effect of nicotine to evoke [3H] 
over?ow. 
The time course of the effect of mecamylamine illustrates 
the pattern and the extent of the inhibition of the nicotine 
evoked increase in fractional release (FIG. 4). Repeated 
measures, two-way AN OVA revealed a signi?cant main 
effect of mecamylamine concentration (F(6)599)=19.59, 
P<0.0001), a signi?cant main effect of time (F(11)599)=4.98, 
P<0.0001), but the concentrationxtime interaction was not 
signi?cant (F(66>599)=0.97, P>0.05). When the data were 
collapsed across time, the lowest concentration of mecamy 
lamine to produce a signi?cant inhibition of nicotine’s effect 
was 0.01 pM. The time course illustrates the small, but 
signi?cant, inhibition (36%) of nicotine’s effect produced by 
this low concentration of mecamylamine. Interestingly, the 
inhibitory effect of 0.01 pM mecamylamine was not detected 
when the results were expressed as total [3H]over?ow (See 
Table 2). The maximal inhibitory effect of the highest 
concentration (100 pM) of mecamylamine is also illustrated 
in FIG. 4 for comparison. 
TABLE 2 
Mecamylamine Inhibition of Nicotine (10 ,uM)-evoked [3H]Overflow 
from Rat Striatal Slices Preloaded with [3H]DA* 
Mecamylamine Total [3H]Overflow 
0 5.60 1 1.20 
0.01 3.57 1 1.52 
0.1 2.40 1 0.87" 
1 1.59 1 0.64** 
10 1.02 1 0.43** 
100 0.54 1 0.32** 
*Slices were superfused with buffer in the absence or presence of mecamy 
lamine (0.01-100 ,uM) for 60 min, followed by 60 min superfusion with the 
addition of 10 ,uM of nicotine to the buffer containing the various concen 
trations of mecamylamine. Data are presented as mean 1 SE. total [3H] 
overflow. Total [3H]overflow for slices superfused in the absence of any drug 
was 0.06 1 0.06. Slices superfused with nicotine (10 ,uM) in the absence of 
mecamylamine were considered control for statistical analysis. 
*P < 0.05, one-tailed, different from control; 
*"P < 0.05, two-tailed, different from control; Dunnett’s post hoc test. n = 8 
rats 
The ability of mecamylamine (1—100 pM) to inhibit 
lobeline (0.1—100 pM)-evoked total [3H]over?ow is shown 
in Table 3. Concentrations of mecamylamine which signi? 
cantly inhibited nicotine-evoked [3H]over?ow were utilized 
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in these experiments. The effect of lobeline (0.1—100 pM) in 
the absence of mecamylamine represented control. Two-way 
AN OVA revealed a signi?cant main effect of lobeline con 
centration (within groups factor, F(4)56)=603.84, P<0.0001); 
however, both the main effect of mecamylamine concentra 
tion (between-groups factor, F(3)14)=2.79, P>0.05) and the 
lobeline><mecamylamine interaction were not signi?cant 
(F(12)56)=1.30, P>0.05). Thus, lobeline-evoked [3H]over?ow 
was not inhibited by mecamylamine. 
TABLE 3 
Lobeline-evoked [3H]Overflow from Rat Striatal Slices Preloaded 
with [3H]DA is Not Inhibited bv Mecamylamine" 
Meca 
mylamine 
Concen 
tration Lobeline Concentration (MM) 
(,uM) 0.1 1 3 10 100 
0 0.6 1 0.4 2.0 1 0.6 10.3 1 0.8 31.9 1 2.2 185.0 1 12 
1 0.9 1 0.5 4.9 1 1.8 10.8 1 1.4 32.5 1 1.0 180.0 1 47.6 
10 0.8 1 0.3 2.4 1 0.5 8.2 1 1.5 41.0 1 6.2 179.5 1 12.2 
100 0.5 1 0.4 0.7 1 0.1 6.5 1 0.9 20.0 1 2.0 160.4 1 30.2 
*Slices were superfused with buffer in the absence or presence of mecamy 
lamine (1-100 ,uM) for 60 min, followed by 60 min superfusion with the 
addition of lobeline (0.1-100 ,uM) to the buffer. Data are presented as mean 
1 SE. total [3H]over?ow. n = 4—6 rats. 
The effect of nicotine and lobeline on [3H]DA uptake into rat 
striatal synaptosomes and synaptic vesicles 
To determine if modulation of DA uptake contributed to 
the increase in [3H]over?ow evoked by nicotine or lobeline, 
[3H]DA uptake into striatal synaptosomes and synaptic 
vesicles was determined (FIG. 5). Nicotine did not inhibit 
[3H]DA uptake into striatal synaptosomes over the concen 
tration range (0.001 nM—100 MM) examined. Before deter 
mining the effect of nicotine on synaptic vesicular [3H]DA 
uptake, the purity of the isolated synaptic vesicle preparation 
was determined by electron microscopy of representative 
vesicle preparations. Plain spheroid or ellipsoid synaptic 
vesicle pro?les of approximately 50 nm in diameter were the 
predominant membrane structures observed. Very few 
(2 1%) contaminating membrane fragments were present. 
The effect of nicotine on [3H]DA uptake into synaptic 
vesicles was analyzed by repeated-measures, one-way 
AN OVA which revealed a signi?cant nicotine concentration 
effect (F(9>28)=3.30, P<0.05). However, Dunnett’s post hoc 
analysis revealed that signi?cant inhibition of uptake only 
occurred at very high concentration (1 mM) of nicotine. 
Lobeline inhibited [3H]DA uptake into synaptopsomes in 
a concentration-dependent manner (FIG. 5). Repeated 
measures, one-way AN OVA revealed a signi?cant lobeline 
concentration effect (F(9)38)=154.0, P<0.0001). The lowest 
concentration of lobeline to produce a signi?cant inhibition 
in the synaptosomal preparation was 30 pM. The IC5O for 
lobeline to inhibit uptake into synaptosomes was 80112 pM. 
Moreover, in contrast to nicotine, lobeline potently inhibited 
[3H]DA uptake into synaptic vesicles in a concentration 
dependent manner (F8)26=28.60, P<0.0001). The lowest con 
centration of lobeline to produce a signi?cant inhibition was 
0.3 pM, and complete inhibition was obtained at 10 pM. The 
IC5O value for lobeline to inhibit vesicular uptake was 
0.8810001 pM, which was 2-orders of magnitude lower 
than that for lobeline-induced inhibition of synaptosomal 
[3H]DA uptake. TetrabenaZine (0.001—100 pM), a high 
af?nity and speci?c inhibitor of the synaptic vesicular 
monoamine transporter, signi?cantly inhibited striatal 
vesicular [3H]DA uptake in a concentration-dependent man 
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ner (F 9)28)=23.78, P<0.0001). The IC5O for tetrabenaZine 
Was 77.7113 nM, and the lowest concentration of tetra 
benaZine Which signi?cantly inhibited vesicular uptake Was 
0.07 pM. Complete inhibition Was obtained at 1 pM tetra 
benaZine. Thus, lobeline Was approximately one order of 
magnitude less potent than tetrabenaZine in inhibiting 
vesicular [3H]DA uptake. 
Effect of lobeline on endogenous DA and DOPAC content in 
rat striatum 
The marked increase in [3H]over?oW in response to 
superfusion With high concentrations of lobeline (FIGS. 2 
and 3) and the lobeline-induced inhibition of synaptosomal 
and vesicular [3H]DA uptake (FIG. 5) suggested that super 
fusion With lobeline may deplete striatal DA content. One 
Way ANOVA revealed a signi?cant lobeline concentration 
effect on DA (F(6)41)=15.35, P< 0.0001) and DOPAC 
(F(6>4O)=6.90, P<0.0001) content in superfused striatal slices. 
Superfusion With loW concentrations (0.1—10 pM) of 
lobeline did not alter DA or DOPAC content (data not 
shoWn); hoWever, When slices Were superfused With high 
lobeline concentrations (30—100 pM), lobeline signi?cantly 
depleted endogenous DA content and increased DOPAC 
content compared to a control (FIG. 6). 
To determine if lobeline-induced depletion of endogenous 
DA content occurred after in vivo administration of lobeline 
to rats, lobeline Was administered (s.c.) acutely (0, 1, 3, 10, 
30 mg/kg), intermittently (0, 3, 10 mg/kg, once daily for 
days) or continuously (0, and 30 mg/kg, by osmotic 
minipump delivery for 21 days), and rat striata Were 
obtained for the determination of endogenous DA and 
DOPAC content (See Table 4). TWo-Way AN OVA revealed 
that lobeline did not signi?cantly alter either striatal DA 
(F(4)58)=0.05, P>0.05) or DOPAC (F(4)58)=0.54, P>0.05) 
content. Therefore, lobeline administration in vivo did not 
deplete striatal DA content at any dose of lobeline or any 
treatment regimen examined. 
TABLE 4 
In vivo Administration of Lobeline Does Not Alter DA and DOPAC 
Content in Rat Striatum" 
Lobeline (mg/kg) 
0 1 3 10 30 
DA 739 z 64 756 z 111 761 z 103 841 z 76 665 z 126 
Acute 
Inter- 743 z 57 ND 778 z 27 800 z 41 ND 
mittent 
Chronic 840 z 72 ND ND ND 856 z 144 
DOPAC 84 z 12 81 z 12 89 z 15 82 z 8 72 z 10 
Acute 
Inter- 63 r 6 ND 57 r 12 57 r 3 ND 
mittent 
Chronic 61 r 4 ND ND ND 62 r 10 
*Rat striata Were obtained 1 hr after acute lobeline administration (0, 1-30 
mg/kg, s.c.); after intermittent lobeline administration (0,3 and 10 mg/kg, 
once daily injection for 10 days, s.c.); and after chronic lobeline delivery by 
osmotic minipump (0 and 30 mg/kg/day for 21 days, s.c.). Data are presented 
as mean : S.E. ng/mg protein. ND: not determined. n = 6-8 rats/group. 
The invention Will noW be discussed by Way of certain 
examples, Which illustrate, but do not limit, the invention. 
EXAMPLES 
Materials 
S(—)Nicotine ditartrate, nomifensine maleate, mecamy 
lamine hydrochloride, and GBR 12909 Were purchased from 
Research Biochemicals, Inc. (Natick, Mass.). TetrabenaZine 
Was purchased from Fluka Chemika-BioChemika 
(Ronkonkoma, N.Y.). [3H]Dopamine ([3H]DA; 3,4 
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dihydroxyphenylethyl(2-[N-3H])amine; speci?c activity, 
25.6 Ci/mmol) Was purchased from NeW England Nuclear 
(Boston, Mass.). Dopamine hydrochloride, 3,4 
dihydroxyphenylacetic acid (DOPAC), 3,4 
dihydroxybenZylamine hydrobromide (DHBA), lobeline 
hemisulfate, pargyline hydrochloride, HEPES (N-[2 
hydroxyethyl piperaZine]-N‘-[2-ethanesulfonic acid]), 
potassium tartrate, adenosine 5‘-triphosphate magnesium 
salt (ATP-Mg2+), L(+)tartaric acid and 1-octanesulfonic acid 
sodium salt Were purchased from Sigma Chemical Co. (St. 
Louis, Mo ot-D-Glucose and sucrose Were purchased from 
Aldrich Chemical Co., Inc. (MilWaukee, Wis.). Ascorbic 
acid Was purchased from AnalaR (BHD Ltd., Poole, Glutar ldehyde, osmiu tetroxide and copper grids Were 
purchased from EMS Inc. (Fort Washington, Calif.). 
Eponate 12 Was purchased from Ted Pella, Inc. (Redding, 
Calif.). TS-2 tissue solubiliZer Was purchased from Research 
Products International (Mount Prospect, Ill.). Acetonitrile 
(HPLC grade) Was purchased from EM Science (EM 
Industries, N] All other chemicals Were purchased from 
Fisher Scienti?c (Pittsburgh, Pa.). 
Subjects 
Male Sprague-DaWley rats (200—250 g) Were obtained 
from Harlan Laboratories (Indianapolis, Ind.) and Were 
housed tWo per cage With free access to food and Water in 
the Division of Lab Animal Resources at the College of 
Pharmacy at the University of Kentucky. Experimental 
protocols involving the animals Were in strict accordance 
With the NIH Guide for the Care and Use of Laboratory 
Animals and Were approved by the Institutional Animal Care 
and Use Committee at the University of Kentucky. 
Example 1 
In Vivo Administration of Lobeline 
For acute administration studies, lobeline (1, 3, 10 and 30 
mg/kg) or vehicle (distilled Water) Was administered subcu 
taneously (s.c.) acutely, and striata Were obtained 1 hr after 
injection for determination of endogenous DA and DOPAC 
content. For intermittent chronic administration studies, 
lobeline (3 and 10 mg/kg) or vehicle Was administered so 
once daily for 10 days. Rats Were killed 24 hrs after the last 
injection and striata Were obtained immediately for deter 
mination of endogenous DA and DOPAC content. For 
continuous chronic administration, an osmotic minipump 
(ALZET 2mL4 model, ALZA Corporation, Palo Alto, Calif.) 
containing 152 mg/ml of lobeline Was implanted so under 
ether anesthesia. A How rate of 2.5 pal/hr delivered lobeline 
(30 mg/kg/day) or vehicle continuously for a 21-day period. 
Striata Were obtained for endogenous DA and DOPAC 
content determination 21 days after osmotic minipump 
implantation. Lobeline dose Was expressed in terms of mg of 
lobeline hemisulfate salt per kg body Weight. 
Example 2 
[3H]DA Release Assay 
The effect of lobeline and nicotine on [3H]over?oW from 
rat striatal slices preloaded With [3H]DA Was determined 
using a previously published method (DWoskin and 
Zahniser, 1986). Rat striata Were rapidly dissected on ice and 
Were sliced using a McIlWain tissue chopper. Slices (500 
pm, 6—8 pg) Were incubated in Krebs’ buffer (in mM; 118 
NaCl, 4.7 KCl, 1.2 MgCl2, 1.0 NaH2PO4) 1.3 CaCl2, 11.1 
ot-D-glucose, 25 NaHCO3, 0.11 L-ascorbic acid, and 0.004 
EDTA (ethylenediamine tetraacetic acid), pH 7.4 and satu 
rated With 95% O2/5% CO2) in a metabolic shaker at 34° C. 
for 30 min to alloW for recovery of responsiveness. Slices 
Were rinsed With 15 ml fresh buffer and then incubated in 
fresh buffer containing 0.1 pM [3H]DA (6—8 slices/3 ml) for 
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an additional 30 min. Subsequently, slices Were rinsed With 
15 ml fresh buffer and transferred to a glass superfusion 
chamber. Slices Were superfused at 1 ml/min With Krebs’ 
buffer (34° C., pH 7.4, aerated With 95% O2/5% CO2) 
containing nomifensine (10 MM), a DA uptake inhibitor, and 
pargyline (10 MM), a monoamine oxidase inhibitor, to ensure 
that [3H]over?oW primarily represented [3H]DA, rather than 
[3H]DA metabolites (Cubeddu et al., 1979; Zumstein et al., 
1981; Rapier et al, 1988). After 60 min of superfusion When 
basal out?ow Was stabiliZed, tWo 5-min samples (5 ml) Were 
collected to determine basal [3H]out?oW. 
For the nicotine or lobeline concentration-response 
studies, a single concentration of either nicotine (0.001—100 
pM) or lobeline (0.01—100pM) Was added to the superfusion 
buffer of individual chambers after the collection of the 
second basal sample, and the drug remained in the buffer for 
60 min or until the end of experiment. Each chamber Was 
exposed to only one concentration of nicotine or lobeline. 
The concentration-response for each drug Was determined 
using a repeated-measures design. In each experiment, one 
slice from the same rat Was superfused in the absence of 
drug and served as control. To determine the calcium 
dependency of the effect of lobeline, concentration-response 
experiments Were performed as described above, hoWever, 
slices Were superfused in the absence of CaCl2, and 0.5 mM 
EGTA Was added to the superfusion buffer. 
To determine the ability of mecamylamine to antagoniZe 
nicotine-evoked [3H]over?oW, a repeated-measure design 
Was utiliZed also. Individual slices Were superfused With a 
single concentration (0.01—100 pM) of mecamylamine for 
60 min, folloWed by 60 min of superfusion With nicotine (10 
pM) in the presence of the various mecamylamine concen 
trations. One slice in each experiment Was superfused in the 
absence of mecamylamine to determine the effect of nicotine 
alone. A control slice Was superfused With buffer alone. To 
determine the ability of mecamylamine to antagoniZe 
lobeline-evoked [3H]over?oW, a betWeen-groups design Was 
utiliZed. Slices Were superfused for 60 min in the absence or 
presence of different concentrations (1—100 MM) of 
mecamylamine, a betWeen-group factor, folloWed by super 
fusion for 60 min With a range of concentrations (0.1—100 
pM) of lobeline, a Within-group factor. 
At the end of each experiment, each slice Was solubiliZed 
With TS-2, and Was incubated at room temperature over 
night. The pH and volume of the solubiliZed tissue samples 
Were adjusted to those of the superfusate samples. Radio 
activity in the superfusate and tissue samples Was deter 
mined by liquid scintillation counting (Packard model 
B1600 TR Scintillation Counter) With an ef?ciency of 59%. 
Fractional release for each superfusate sample Was cal 
culated by dividing the tritium collected in each sample by 
the total tritium present in the tissue at the time of sample 
collection. Fractional release Was expressed as a percentage 
of total tritium in the tissue at the time of sample collection. 
Basal out?oW Was calculated from the average of the tritium 
collected in the tWo 5-min samples just before the addition 
of drug. Nicotine or lobeline-evoked [3H]over?oW Was 
calculated by summing the increases in collected tritium 
resulting from exposure to drug and subtracting the basal 
out?oW for the equivalent period of drug exposure. 
Example 3 
Determination of Endogenous DA and DOPAC Content in 
Striatal Slices FolloWing Superfusion With Lobeline 
To determine if lobeline exposure depleted endogenous 
DA content in the striatal slices, superfusion experiments 
Were performed exactly as described above, except that 
slices Were preloaded With 0.1 pM unlabeled DA, rather than 
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the same concentration of [3H]DA. At the end of the 
superfusion experiment, slices Were processed in the endog 
enous DA and DOPAC content assay described beloW. 
Example 4 
Striatal DA and DOPAC Content Assay 
Striatal slices from superfusion experiments and striatal 
tissue from rats administered lobeline or vehicle in in vivo 
studies Were assayed for endogenous DA and DOPAC 
content by a modi?cation of a previously described method 
(Dubocovich and Zahniser, 1985). An aliquot (500pl) of 
0.1M perchloric acid (pH 1.0) containing 0.14—0.29 pM 
3,4-dihydroxybenZylamine hydrobromide (DHBA, internal 
standard) Was added to 100 mg of striatum and the mixture 
Was sonicated With an Ultrasonic Processor (40-Watt Model, 
Sonics & Materials, Danbury, Conn.). The homogenate Was 
centrifuged at 30,000><g for 10 min at 4° C., and the 
supernatant Was ?ltered (0.2 pm nylon membrane). An 
aliquot (50pl) of the ?ltrate (1:1, 1:50, 1:100, 1:200 or 1:500 
dilution With 0.1M perchloric acid) Was injected onto the 
high pressure liquid chromatograph With electrochemical 
detection (HPLC-EC) system. The HPLC-EC system con 
sisted of syringe loading injector (Model 7725, Rheodyne 
L.P., Cotati, Calif.), Beckman Model 116 HPLC pump 
(Beckman, Fullerton, Calif.), ESA ODS ultrasphere C18 
reverse-phase column (4.6 cm><75 mm, 3 micron particle 
siZe, ESA, Bedford, Mass.), and an ESA 5100A coulometric 
electrochemical detector With a model 5011 detector cell 
(E1=+0.05 V, E2 =+0.32 V). The eluent Was 6% acetonitrile, 
10 pM EDTA, 1.4 mM 1-octane-sulfonic acid and 76 mM 
sodium phosphate monobasic (pH 3.1). All separations Were 
performed at room temperature at a How rate of 1 ml/min. 
Complete separation of DA and DOPAC and 
re-equilibration of the system required 9 min. The retention 
time of DA, DOPAC and DHBA standards Was used to 
identify the relevant peak. Peak heights Were used to cal 
culate the detected amount of compound based on standard 
curves. The detection limit of DA and DOPAC Was 0.2 and 
0.05 pg/50 pl injected, respectively. Recovery of internal 
standard Was routinely 75%. 
Example 5 
[3H]DA Uptake Assay, Striatal Synaptosomal Preparation 
The uptake of [3H]DA into striatal synaptosomes Was 
determined using a modi?cation of a previously published 
method (Masserano et al., 1994). The striata from a single rat 
Were homogeniZed in 20 ml cold 0.32M sucrose With 5 mM 
NaHCO3 (pH 7.4) With 16 up and doWn strokes of a 
TEFLON pestle homogeniZer (clearance approximately 
0.003 inches). The homogenate Was centrifuged at 2,000><g 
for 10 min at 4° C. The supernatant Was centrifuged at 
20,000><g for 15 min at 4° C. The pellet Was resuspended in 
2 ml assay buffer (in mM; 125 NaCl, 5KCl, 1.5 MgSO4, 1.25 
CaCl2, 1.5 KH2PO4, 10 ot-D-glucose, 25 HEPES, 0.1 
EDTA, 0.1 pargyline, 0.1 ascorbic acid, and saturated With 
95% O2/5% CO2, pH 7.4). The ?nal protein concentration 
Was 400 pig/ml. The assay Was performed in duplicate in a 
total volume of 500 pl. Aliquots (50 pl containing 20 pg of 
protein) Were incubated With 50 pl of nicotine (?nal con 
centration 0.001 nM—100 pM) or 50 pl of lobeline (?nal 
concentration, 0.01—1000 pM) in a metabolic shaker at 34° 
C. for 10 min. Subsequently, a ?nal DA ([3H]DA/cold DA) 
concentration of 0.32 pM Was added to each tube in a total 
volume of 66 pl, consisting of 16 pl of 0.01 pM [3H]DA and 
50 pl of 3 pM unlabelled DA. The incubation continued for 
10 min at 34° C. The reaction Was terminated by the addition 
of 3 ml cold assay buffer (Without 1 mM catechol). Samples 
Were rapidly ?ltered through a Whatman GF/B ?lter using a 
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Brandel cell harvester (model MP-43RS, Biochemical 
Research and Development Laboratories, Inc., 
Gaithersburg, Md.) and the ?lter Was subsequently Washed 
3 times With 4 ml of cold assay buffer containing 1 mM 
catechol. Filters Were previously soaked for 2 hrs in the cold 
assay buffer containing 1 mM catechol. Nonspeci?c uptake 
Was determined in duplicate samples in the presence of 10 
pM GBR 12909. Filters Were placed into scintillation vials, 
10 ml of scintillation cocktail Was added and radioactivity 
Was determined by scintillation spectrometry. 
Example 6 
[3H]DA Uptake, Striatal Synaptic Vesicle Preparation 
The uptake of [3H]DA into striatal synaptic vesicles Was 
determined using previously published methods (Erickson et 
al., 1990). Striata from 3 rats Were pooled and homogeniZed 
in 0.32M sucrose (pH 7.5, 500 mg/14 ml) With 10 up and 
doWn strokes of a TEFLON pestle (clearance approximately 
0.009 inches) over a 2 min period. The homogenate Was then 
centrifuged at 2,000><g for 10 min at 4° C. and the resulting 
supernatant Was centrifuged at 10,000><g for 30 min at 4° C. 
Synaptosomes (buffy coat) Were separated from the under 
lying mitochondria and cellular debris (reddish pellet) by 
gentle sWirling in 2 ml of 0.32M sucrose. The enriched 
synaptosome fraction (2.0 ml) Was subjected to osmotic 
shock by addition of 7 ml distilled H20 and Was homog 
eniZed With 5 up and doWn strokes of the TEFLON pestle. 
The osmolarity Was restored by the addition of 900 pl of 
0.25M HEPES and 900 pl of 1.0M neutral potassium-tatrate 
buffer (pH 7.5) folloWed by a 20 min centrifugation (20, 
000><g at 4° C.). The supernatant Was then centrifuged for 60 
min (55,000><g at 4° C.). One ml of solution containing 10 
mM MgSO4) 0.25M HEPES and 1.0M potassium-tartrate 
buffer Was added to the supernatant and the suspension Was 
centrifuged (100,000><g for 45 min at 4° C.). Immediately 
before use, the ?nal pellet Was resuspended in the assay 
buffer (in mM; 25 HEPES, 100 potassium tartrate, 0.05 
EGTA, 0.10 EDTA, 2ATP-Mg2+, 1.7 ascorbic acid, pH 7.4). 
Aliquots (160 pl containing 8—10 pg protein) of the resus 
pension Were incubated With 20 pl of drug (nicotine, ?nal 
concentration 0.001—1000 pM; lobeline, ?nal concentration 
0.001—100 MM; or tetrabenaZine, ?nal concentration 
0.001—100 pM) and 20 pl of [3H]DA (?nal concentration 0.3 
pM) for 8 min at 37° C. in a total volume of 200 pl. The 
reaction Was terminated by addition 2.5 ml of cold assay 
buffer containing 2 mM MgSO4. Samples Were rapidly 
?ltered through Whatman GF/F ?lters using the Brandel cell 
harvester. The ?lters Were then Washed 3 times With 4 ml of 
cold assay buffer containing 2mM MgSO4. Filters Were 
previously soaked in 0.5% polyethylenimine (PEI) solution 
for 2 hr at 4° C. Nonspeci?c uptake Was determined by 
incubation of duplicate samples at 0° C. in the absence of 
drug. Filters Were placed into scintillation vials, 10 ml of 
scintillation cocktail Was added to each vial, and radioac 
tivity Was determined by scintillation spectrometry. 
Example 7 
Electron Microscopy 
To con?rm the purity of the isolated synaptic vesicles, 
vesicle pellets from rat striata Were processed for electron 
microscopy. The pellet Was ?xed for 2 hr With 3.5% glut 
araldehyde in 0.1M phosphate buffer (pH 7.3). After a brief 
rinse in phosphate buffer, the pellet Was post?xed for 2 hr in 
1% osmium tetroxide in phosphate buffer. The pellet Was 
then dehydrated ?ve times in graded ethanol (50%, 70%, 
80%, 90% and 100%), and embedded in Eponate 12 resin. 
Ultrathin (60—80 nm) sections Were cut on an Ultracut E 
microtome (Reichert-Jung, Inc., Vienna, Austria) and Were 
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collected on copper grids. The sections Were then stained 
With saturated uranyl acetate in 70% ethanol and 0.04M lead 
citrate. The grids Were vieWed With a Hitachi H-7000 
transmission electron microscope (Hitachi, Tokyo, Japan). 
Example 8 
Statistics 
Repeated-measures, one-Way AN OVA Was performed to 
analyZe the results of the folloWing experiments: the con 
centration effect of nicotine or lobeline on [3H]over?oW, the 
ability of mecamylamine to antagoniZe nicotine (10 pM) 
evoked [3H]over?oW, and the effect of lobeline on DA and 
DOPAC content in striatal slices. TWo-Way AN OVAs Were 
used to analyZe the concentration effect of lobeline or 
nicotine on the time course of fractional release, to analyZe 
the calcium-dependency of lobeline-evoked [3H]over?oW 
and to analyZe mecamylamine antagonism of lobeline 
evoked [3H]over?oW. Inhibition of synaptosomal and 
vesicular [3H]DA uptake Were analyZed by repeated 
measures, one-Way ANOVA, and by an iterative nonlinear 
least-squares curve-?tting program (GraphPAD-PRIZM; 
GraphPAD, San Diego, Calif.) to obtain IC5O values. Dun 
nett’s post hoc test Was used to compare treatment means to 
a single control mean. Also, Duncan’s NeW Multiple Range 
Test or Fisher’s LSD post hoc analysis Were used to compare 
pairs of treatment means. Duncan’s NeW Multiple Range 
Test Was used When signi?cant one-Way ANOVA’s Were 
obtained or When signi?cant main effects Were obtained in 
the tWo-Way AN OVA’s. Fisher’s LSD poste hoc analysis is 
a more conservative test, Which takes into account error 
Which cumulates during multiple comparisons of pairs of 
means. Fisher’s LSD analysis Was used When the interaction 
term Was signi?cant in the tWo-Way AN OVAs, speci?cally 
in the post hoc analysis of drug><time interactions. Statistical 
signi?cance Was reached When P<0.05 (tWo-tailed, unless 
otherWise indicated). 
Conclusion 
The results of the present study demonstrate that, similar 
to nicotine, lobeline evokes [3H]over?oW from rat striatal 
slices preloaded With [3H]DA in a concentration-dependent 
manner. HoWever, in contrast to nicotine, lobeline-evoked 
[3H]over?oW is calcium-independent and mecamylamine 
insensitive. Although lobeline is often thought to be a 
nicotinic agonist, the present results suggest that lobeline 
acts to evoke [3H]over?oW via a mechanism other than by 
stimulation of nicotinic receptors. Moreover, in contrast to 
nicotine, lobeline potently inhibits striatal synaptosomal and 
vesicular [3H]DA uptake. Thus, lobeline-induced inhibition 
of DA uptake and alteration of intracellular DA storage may 
contribute to the mechanism responsible for the lobeline 
evoked increase in [3H]over?oW from [3H]DA -preloaded 
striatal slices. 
In agreement With reports of others, nicotine evoked 
[3H]over?oW from superfused rat striatial slices preloaded 
With [3H]DA (Westfall, 1974; Giorguieff-Chesselet et al., 
1979; Westfall et al., 1987; Harsing et al., 1992; Sacaan et 
al., 1995) and from rat or mouse striatal synaptosomes 
(Chesselet, 1984; RoWell et al, 1987; Rapier et al., 1988, 
1990; Grady et al., 1992; RoWell and Hilelbrand, 1992, 
1994; RoWell, 1995). The nicotine concentration range 
(0.001—100 pM) chosen for the present study Was based on 
extensive research demonstrating that at loW concentrations 
(<100 MM), the effect of nicotine Was calcium-dependent 
and antagoniZed by mecamylamine (i.e., nicotinic receptor 
mediated); Whereas at high concentrations (>100 pM), a 
calcium-independent effect Which Was not antagoniZed by 
mecamylamine Was observed (Giorguieff-Chesselet et al., 
1979; Westfall et al., 1987; Rapier et al., 1988, 1990; Grady 
et al., 1992). 
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In previous studies utilizing the slice superfusion assay, 
nicotine Was superfused for only short periods of time (3—10 
min) (Giorguieff-Chesselet et al., 1979; Westfall et al., 1987; 
Harsing et al., 1992; Sacaan et 211., 1995). Only one of these 
reports (Giorguieff-Chesselet et al., 1979) provided the time 
course of the effect of nicotine (1 MM), and in that study, 
[3H]over?oW remained elevated for the entire 10-min period 
of nicotine exposure. The present study illustrates a com 
plete time course of exposure (over a 60 min superfusion 
period) to a low range of nicotine concentrations (0.01—100 
22M) (FIG. 1A), and illustrates the time course and pattern of 
mecamylamine-induced inhibition of the effect of nicotine, 
indicative of nicotinic receptor mediation (FIG. 4). The time 
course illustrates that the peak effect of nicotine Was reached 
Within 10—15 min after the start of superfusion With drug. 
Despite continued superfusion With nicotine, the response 
returned to basal levels Within 25 min, indicative of receptor 
desensitiZation. The present ?ndings are of particular inter 
est considering that in human smokers, a persistent nicotine 
blood level (0.1—pM) has been observed during the Waking 
hours of each day (BenoWitZ et al., 1990). 
Similar to nicotine, lobeline evoked [3H]over?oW from 
[3H]DA-preloaded striatal slices in a concentration 
dependent manner. HoWever, as illustrated by the time 
course (FIG. 2) and the concentration-response curve (FIG. 
3), the pattern and the magnitude of the effect of lobeline 
Was different from that of nicotine. The peak effect occurred 
10—20 min folloWing the start of lobeline exposure and, at 
least at the loW concentrations, the response returned to 
basal levels despite continued superfusion With lobeline. 
HoWever, the response remained signi?cantly above basal 
levels during superfusion With the higher lobeline concen 
trations (30—100 MM). Moreover, the effect of lobeline on 
[3H]over?oW Was markedly increased (8—34 fold) compared 
to the effect of nicotine, particularly at the higher concen 
trations (10—100 22M) examined (FIGS. 1B and 3). 
Additionally, a depletion of endogenous DA and an increase 
in endogenous DOPAC Was observed in the striatal slices 
superfused With these high concentrations of lobe-line, 
indicative of marked DA utiliZation in response to lobeline, 
and potential toxicity, at least in vitro (FIG. 6). Furthermore, 
in contrast to nicotine, the effect of lobeline Was found in the 
present study to be calcium-independent and not inhibited 
by mecamylamine. Thus, despite the reported high af?nity of 
lobeline for the [3H]nicotine binding site, lobeline evidently 
evokes [3H]over?oW from rat striatal slices preloaded With 
[3H]DA by a mechanism other than stimulation of nicotinic 
receptors. 
The present results further demonstrate that, in contrast to 
nicotine, lobeline potently inhibits [3H]DA uptake into stri 
atal synaptosomes and vesicles. Signi?cant inhibition of 
[3H]DA uptake into synaptic vesicles Was observed at a low 
concentration of 0.3 pM of lobeline, and the IC5O for this 
effect Was 0.88 22M (FIG. 5). Additionally, at higher con 
centrations (230 MM), [3H]DA uptake into striatal synap 
tosomes Was also signi?cantly inhibited. The IC5O for 
lobeline-induced inhibition of synaptosomal uptake Was 80 
22M, i.e., tWo orders of magnitude higher than that for 
inhibition of uptake into synaptic vesicles. The present 
results from the synaptosomal assay are in good agreement 
With a previous report of lobeline-induced inhibition of 
[3H]DA uptake into mouse striatal synaptosomes (Debler et 
al., 1988). In the present study, nicotine only inhibited 
vesicular [3H]DA uptake at a very high concentration (~1 
mM) and no inhibition of synaptosomal [3H]DA uptake Was 
observed. The lack of effect of nicotine to inhibit DA uptake 
into striatal synaptosomes is in agreement With previous 
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reports (Kramer et al, 1989; IZenWasser et al., 1991; RoWell 
and Hill, 1993). Using the striatal mince preparation, nico 
tine has been reported to inhibit [3H]DA uptake by an 
indirect mechanism (IZenWasser et al., 1991); hoWever, 
other investigators using the more intact striatal slice prepa 
ration Were unable to observe any nicotine-induced inhibi 
tion of [3H]DA uptake (RoWell and Hill, 1993). 
Interestingly, [3H]DA uptake into [3-NGF-treated PC12 cells 
transfected With the rat DA transporter cDNA Was inhibited 
by nicotine (IC5O=8 MM), and mecamylamine blocked nico 
tine’s effects (Yamashita et al, 1995), suggesting that nico 
tinic receptors may modulate DA uptake. More recently, 
nicotine (0.4 mg/kg) administered so to rats Was observed 
to increase the clearance of exogenously applied DA in an in 
vivo voltammetric study (Hart and Ksir, 1996), suggesting 
nicotine-induced enhancement of DA clearance in striatum 
in vivo. The results of the present study indicate that the 
synaptic vesicular DA transporter is signi?cantly more sen 
sitive to lobeline-induced inhibition than the plasma mem 
brane DA transporter, and that both transport processes are 
not modulated to any great extent by nicotine. Since these 
tWo transporters are structurally and functionally different 
(see revieW, BroWnstein and Hoffman, 1994), it is not 
surprising that they are differentially sensitive to inhibition 
by lobeline. 
The lobeline-induced increase in DA concentration in the 
extracellular space (as re?ected by an increase in [3H] 
over?oW in superfusate in the [3H]DA release assay) is 
consistent With the lobeline-induced inhibition of vesicular 
and synaptosomal DA uptake. Notably, the loWest concen 
tration of lobeline to signi?cantly evoke [3H]over?oW in the 
superfusion assay Was 1 22M, Which is Within the range of 
concentrations observed to speci?cally inhibit vesicular DA 
uptake, since higher concentrations (i.e. >30 22M) Were 
required to detect the inhibition of synaptosomal DA uptake. 
The observation that the lobeline-induced [3H]over?oW is 
not calcium-dependent suggests that the released DA origi 
nated from cytosolic rather than vesicular pools. Since 
lobeline is a very lipophilic compound (BarloW and 
Johnson, 1989; Reavill et al, 1990; Bhat et al., 1991), it 
could easily gain access to the vesicular transporter by 
passive entrance into the neuron and its vesicles. Lobeline 
induced inhibition of vesicular DA uptake could occur via 
tWo mechanisms, dissipation of the vesicle proton gradients 
and/or interaction With a substrate site on the vesicular 
transporter. Because lobeline is a Weak base, and as a result 
of the loWer pH inside the vesicle, lobeline could accumulate 
in synaptic vesicles in its charged form (i.e. protonated). 
Once lobeline exceeded the buffering capacity Within the 
vesicle, the vesicular pH gradient Would be attenuated With 
a resulting decrease in available energy for DA uptake 
(Beers et al., 1986; Johnson, 1988). Subsequently, 
uncharged DA Would diffuse out of the vesicles in accor 
dance With the concentration gradient, such that DA con 
centrations in the cytosol Would increase. Elevation of 
cytosolic DA Would promote reverse transport and DA 
release from the presynaptic terminal into the extracellular 
space. Furthermore, neurotoxicity may result from the 
increased cytosolic DA, Which could likely undergo auto 
oxidation and enZymatic oxidative metabolism, leading to 
the increased formation of DOPAC, hydrogen peroxide, free 
radicals, and active quinones (Graham et al., 1978; Slivka 
and Cohen, 1985). Thus, lobeline-induced redistribution of 
intracellular DA Within the presynaptic terminal Would 
result in DA release and potential neurotoxicity. 
Taken together, lobeline appears to act in an 
amphetamine-like manner as a DA releasing agent. Amphet 
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amine is lipophilic, entering neurons by passive diffusion 
(Ross and Renyi, 1966; Fischer and Cho, 1989; Liang and 
Rutledge, 1982). At loW concentrations, amphetamine enters 
neurons via the DA transporter; and as a result, DA is 
released into the extracellular space by carrier-mediated 
exchange diffusion (Fischer and Cho, 1979; Liang and 
Rutldege, 1982), a calcium-independent mechanism Which 
is sensitive to DA uptake inhibitors (Hurd and Ungerstedt, 
1989; Parker and Cubeddu, 1986; ZacZek et al., 1991; Levi 
and Raiteri, 1993). Furthermore, amphetamine is a Weak 
base Which has been reported to interact With the vesicular 
substrate site (Schuldiner et al, 1993; GonZaleZ et al., 1994), 
to enter synaptic vesicles, and dissipate the vesicular proton 
gradient resulting in intracellular redistribution and subse 
quent release of neurotransmitter (Knepper et al., 1988; 
SulZer and Rayport, 1990; SulZer et al., 1995). In compari 
son With amphetamine, feW studies have focused on the 
mechanism of action of lobeline; hoWever, the present 
?ndings indicate many similarities in the action of these tWo 
drugs, even though lobeline has often been categoriZed as a 
nicotinic agonist (Decker et al, 1995). 
The current observation, that superfusion of striatal slices 
With high concentrations (30—100 pM) of lobeline resulted 
in signi?cant DA depletion, led us to evaluate striatal DA 
content folloWing acute, intermittent and chronic in vivo 
lobeline administration to rats. Only one study has reported 
a brain concentration (0.6 pM) of lobeline 15 min folloWing 
in vivo administration (4 mg/kg, sc) to rats (Reavill et al., 
1990). Thus, in the present study, in order to obtain higher 
brain concentrations, lobeline Was administered to rats in 
doses up to 30 mg/kg for 21 days. No effect on endogenous 
DA or DOPAC content Was observed folloWing any dose or 
treatment regimen of lobeline administration. The present 
results are in agreement With a previous study in Which 
lobeline Was administered acutely at a single dose (10 
mg/kg, ip) and no effect on DA striatal content Was 
observed (Westfall et al., 1967). The highly lipophilic nature 
of lobeline and its ability to cross the blood-brain barrier 
results in a higher brain/plasma ratio compared to nicotine 
folloWing s.c. administration (BarloW and Johnson, 1989; 
Reavill et al., 1990; Bhat et al., 1991). Due to the physico 
chemical characteristics of lobeline, high concentrations in 
brain after in vivo administration (as are required in the 
superfusion buffer to observe the striatal DA depletion) may 
not be achieved due to metabolic/pharmacokinetic factors. 
Furthermore, chronic administration of lobeline via osmotic 
minipump may not have delivered the expected dose, due to 
potential instability of the drug at 37° C. for prolonged time 
periods (Dr. Yvonne Boyer, DynaGen, Inc., personal 
communication). HoWever, striatal DA depletion Was not 
observed folloWing 10 days of intermittent administration of 
10 mg/kg, prepared fresh each day Without the possibility of 
lobeline instability. Nevertheless, the use of lobeline as a 
long-term smoking cessation therapy should be carefully 
evaluated With respect to potential CNS neurotoxicity, par 
ticularly in light of the apparent similarities of lobeline and 
amphetamine, and the knoWn neurotoxicity of amphetamine 
and its analogs (Sonsalla, 1995). 
In summary, lobeline evoked [3H]over?oW from rat stri 
atal slices preloaded With [3H]DA, in a concentration 
dependent, calcium-independent and mecamylamine 
insensitive manner. A lobeline-induced inhibition of 
synaptic vesicular DA transport and subsequent redistribu 
tion of presynaptic DA storage may be the mechanism by 
Which lobeline evokes DA release. Clearly, lobeline evokes 
DA release by a mechanism different from that of nicotine, 
Which may explain the reported differences in the behavioral 
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effects of these drugs, and the differences in their abilities to 
upregulate nicotinic receptors folloWing chronic administra 
tion. 
Although the present invention has been discussed here 
inabove by Way of examples for the purpose of illustration 
and clarity of understanding, it should be appreciated that 
the scope of the invention is instead de?ned by the appended 
claims and equivalents thereof. 
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What is claimed is: 
1. A method of treating an individual for dependence on 
a drug of abuse, WithdraWal from a drug of abuse, or for an 
eating disorder, Wherein said drug of abuse is selected from 
the group consisting of cocaine, amphetamines, caffeine, 
phencyclidine, opiates, barbiturates, benZodiaZepines, 
cannabinoids, hallucinogens and alcohol, comprising 
administering to the individual an effective amount of a 
compound having the formula 
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Wherein R1 and R2 are independently H, loWer alkyl, loWer 
alkenyl, loWer alkylcarbonyl, phenylcarbonyl, 
alkylphenylcarbonyl, loWer alkoXycarbonyl, loWer 
alkylaminocarbonyl, higher alkylcarbonyl, and poly 
(alkyleneoXide)carbonyl; R3 is H or combines With R1 to 
form a double bond; R4 is H or combines With R2 to form 
a double bond; and X is H or loWer alkyl, or pharmaceuti 
cally acceptable salt thereof. 
2. The method of claim 1, Wherein the compound is 
selected from the group consisting of lobeline, lobelanidine, 
lobelanine, and pharmaceutically acceptable salts thereof. 
3. The method of claim 1, Wherein the compound is 
lobeline, and pharmaceutically acceptable salts thereof. 
4. The method of claim 1, Wherein said administering is 
performed subcutaneously, intramuscularly, intravenously, 
transdermally, orally, intranasally, or rectally. 
5. The method of claim 1, Wherein said administering of 
lobeline induces release of dopamine from cells of the 
central nervous system of the individual. 
6. The method of claim 1, Wherein said administering of 
lobeline inhibits uptake of dopamine by cells of the central 
nervous system of the individual. 
7. The method of claim 1, Wherein the eating disorder 
includes obesity of the individual. 
8. The method of claim 1, Wherein the individual’s desire 
for said drug of abuse or for food is reduced for at least one 
day. 
9. The method of claim 1, further comprising administer 
ing behavior modi?cation counseling to the individual. 
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